Cara Therapeutics is developing novel therapies to treat the symptoms of chronic pain. Existing treatments carry cardiovascular risk and, in many cases, simply fail to adequately provide comfort-giving Cara an opportunity to make a real impact on patients' lives. Pillsbury's work for Cara began when we advised on its incorporation but quickly grew to include advice on corporate governance, finance, intellectual property and licensing. During Cara's first year in business, Pillsbury advised on two rounds of venture financing that funded the company's initial clinical trials. Positive data from those trials led to a development and co-promotion agreement with ALZA Corp., a division of Johnson & Johnson-giving Cara a first-tier development partner when it was just a one-year-old company.